TScan Therapeutics, Inc. Common Stock (TCRX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TScan Therapeutics, Inc. Common Stock (TCRX) is listed on Nasdaq, where it has traded since July 16, 2021.
- Listed On
- Nasdaq
- Listed Since
- July 16, 2021
- Employees
- 142
- Market Cap
- $23M
About TScan Therapeutics, Inc. Common Stock
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 57 institutions reported holding TCRX, with 35.8 million shares worth $35.1 million in aggregate. The largest reported holder was Lynx1 Capital Management, with 8.0 million shares worth $7.9 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Lynx1 Capital Management | 8,019,148 | $8M | Unchanged |
| Bvf Inc/IL | 5,564,290 | $5M | Unchanged |
| Baker Bros. Advisors | 2,784,792 | $3M | Unchanged |
| Vanguard | 2,556,449 | $3M | Added 2.38% |
| Two Sigma Investments | 1,949,604 | $2M | Added 61.26% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is TCRX?
TScan Therapeutics, Inc. Common Stock (TCRX) is listed on Nasdaq, where it has traded since July 16, 2021.
Who are the largest institutional holders of TCRX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of TCRX were Lynx1 Capital Management, Bvf Inc/IL and Baker Bros. Advisors.
How many institutions own TCRX?
57 institutions reported a position in TCRX for the quarter ended June 30, 2026, worth $35.1 million in total.
Did institutions buy or sell TCRX last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for TCRX.
Every reported institutional holder, plus insider and congressional trades in TCRX, on SentiSense.